4D Molecular Therapeutics, Inc. Total Contract Liability
4D Molecular Therapeutics, Inc. (FDMT) had Total Contract Liability of $1.31 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2024-11-13
- 2024-09-30: Contract with Customer, Liability $1.31M.
- 2024-06-30: Contract with Customer, Liability $1.32M.
- 2024-03-31: Contract with Customer, Liability $1.32M.
- 2023-12-31: Contract with Customer, Liability $1.25M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2024-09-30 | $1.31M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.32M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.32M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.25M 10-Q · filed 2024-11-13 | |
| 2023-09-30 | $1.23M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.42M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.66M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.96M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $3.21M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $3.71M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $3.87M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $5.09M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $4.74M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $5.36M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $18.78M 10-Q · filed 2021-05-13 | |
| 2021-01-01 | $1.30M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $19.81M 10-K · filed 2022-03-28 | |
| 2020-01-01 | $900.00K 10-Q · filed 2021-05-13 | $3.20M 10-K · filed 2021-03-25 |
| 2019-12-31 | $19.47M 10-K · filed 2021-03-25 | |
| 2019-01-01 | $3.60M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |